<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgical resection of localized renal cell carcinoma (RCC) can be curative for localized disease, but many patients eventually recur. In addition, many RCCs are clinically silent for much of their course, and the initial diagnosis can be delayed until disease is either locally advanced and unresectable or metastatic. The natural history of disease for patients with advanced or metastatic RCC can vary widely from a few months to many years depending on the clinical, pathologic, laboratory, and radiographic features of disease, as well as the response to therapy.</p><p>Understanding the molecular pathogenesis of RCC has identified targets for therapeutic intervention  (<a class="graphic graphic_figure graphicRef76708" href="/d/graphic/76708.html" rel="external">figure 1</a>) and led to the development of multiple agents that have an important role in the management of patients with advanced RCC. Antiangiogenic and molecularly targeted agents and their application in patients with advanced RCC will be reviewed here, with the primary focus on the treatment of clear cell RCC because much of the data have been derived from clinical trials in these patients.</p><p>An overview of the treatment approach to RCC, prognostic factors in RCC, and the role of immunotherapy alone or in combination with antiangiogenic agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MOLECULAR PATHOGENESIS</span><span class="headingEndMark"> — </span>Approximately 65 to 75 percent of renal epithelial tumors are clear cell carcinomas; other important subtypes include papillary (chromophilic), chromophobe, collecting duct, and medullary carcinomas, as well as oncocytomas. The different RCC subtypes are increasingly being characterized by unique genetic abnormalities and associated gene expression patterns [<a href="#rid1">1,2</a>]. The pathogenesis of clear cell carcinoma is the best understood. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Genomic alterations in clear cell carcinoma'</a>.)</p><p>The initial insights into the molecular pathogenesis of clear cell RCC came from studies on Von Hippel-Lindau (VHL) disease. VHL is characterized by the development of cerebellar and spinal hemangioblastomas, retinal angiomas, pheochromocytomas, and renal cysts and tumors. Clear cell RCCs develop in 40 to 60 percent of patients with VHL disease; these tend to be multicentric and bilateral with an unusually early age of onset. (See  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p>Genetic analyses of VHL-associated RCCs showed loss of heterozygosity at the VHL locus on chromosome 3p25, and the same abnormality is present in 75 to 80 percent of sporadic clear cell RCCs. These findings implicated the VHL gene in the pathogenesis of clear cell RCCs. This abnormality results in the overproduction of vascular endothelial growth factor (VEGF). (See  <a class="medical medical_review" href="/d/html/5195.html" rel="external">"Molecular biology and pathogenesis of von Hippel-Lindau disease"</a>.)</p><p>VEGF is probably the most important growth factor that is involved in tumor angiogenesis, and it plays a significant role in the growth and progression of many types of human cancer, including RCC. Elucidation of the downstream pathways from the VEGF receptor (VEGFR) has defined a number of targets for interruption of the signaling that results in angiogenesis  (<a class="graphic graphic_figure graphicRef76708" href="/d/graphic/76708.html" rel="external">figure 1</a>). (See <a class="local">'Inhibitors of the VEGF pathway'</a> below and  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors", section on 'VEGF receptors'</a>.)</p><p>An alternative pathway is mediated by the mechanistic target of rapamycin (mTOR), which is downstream of the phosphoinositide 3-kinase and Akt and is regulated by the phosphatase and tensin homolog (<em>PTEN</em>) tumor suppressor gene. Inhibition of this pathway leads to decreased protein translation and inhibition of both angiogenesis and tumor cell proliferation. (See <a class="local">'Inhibitors of the mTOR pathway'</a> below.)</p><p class="headingAnchor" id="H471560809"><span class="h1">OVERVIEW OF APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>The integration of antiangiogenic and molecularly targeted therapy into the overall management of patients with advanced clear cell RCC is discussed here. The timing of these agents relative to checkpoint inhibitor immunotherapy and the efficacy of combined immunotherapy plus antiangiogenic therapy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p>Multiple agents targeting the vascular endothelial growth factor (VEGF) pathway and drugs inhibiting the mechanistic target of rapamycin (mTOR) are active and approved for the management of advanced clear cell RCC. The integration and choice of initial systemic therapy in patients with advanced or metastatic RCC are outlined here  (<a class="graphic graphic_algorithm graphicRef116262" href="/d/graphic/116262.html" rel="external">algorithm 1</a>), and details of the specific targeted agents are provided below.</p><p>The choice of treatment for patients with advanced disease has been based on prognostic risk factors historically developed in the era of frontline VEGF tyrosine kinase inhibitors (TKIs). The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model integrates six adverse factors to stratify patients into favorable-, intermediate-, or poor-risk groups  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. </p><p>The relevance of the IMDC prognostic criteria in the era of frontline combination immunotherapy remains to be established. In the absence of alternative immunotherapy-based prognostic criteria, these criteria continue to be used in clinical trials to risk-stratify patients and, to some extent, by providers and clinical guidelines to direct therapy. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Risk stratification'</a>.)</p><p class="headingAnchor" id="H97678800"><span class="h1">INHIBITORS OF THE VEGF PATHWAY</span><span class="headingEndMark"> — </span>Vascular endothelial growth factor (VEGF) pathway inhibitors, used principally in combination with checkpoint inhibitor immunotherapy, are important agents in the initial treatment of patients with advanced or metastatic RCC. Some agents also have an established role in the treatment of patients who are ineligible for immunotherapy-based combinations as well as those refractory to prior courses of immunotherapy and/or molecularly targeted therapy. </p><p>While a number of agents are available, there are only limited data comparing all these agents directly. Available options include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs), such as <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a> (see <a class="local">'Preferred VEGFR inhibitors'</a> below and <a class="local">'Other agents'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a>, a monoclonal antibody that targets circulating VEGF, in combination with interferon alfa (see <a class="local">'Bevacizumab plus interferon alfa'</a> below)</p><p></p><p>The mechanism of action of these agents is interruption of the VEGF signaling pathway, which leads to death of vascular endothelial cells causing hypoxic stress (necrosis) within tumor cells. This hypoxic stress ultimately leads to physiologic angiogenic escape as new vasculature forms under the influence of alternative pro-angiogenic factors induced by hypoxia. Since this resistance tends to be plastic (eg, tumor vasculature prefers to be supported by VEGF), some tumors can respond to retreatment with the same antiangiogenic agent after a drug holiday (eg, rechallenge with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid4">4</a>] or <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> [<a href="#rid5">5</a>]), or sequential therapy with different antiangiogenic agents [<a href="#rid6">6-11</a>]. (See <a class="local">'Preferred VEGFR inhibitors'</a> below.) </p><p class="headingAnchor" id="H3"><span class="h2">Preferred VEGFR inhibitors</span><span class="headingEndMark"> — </span>Multiple VEGF receptor (VEGFR) TKIs are active against RCC. Although there are differences among these agents, some toxicities are common to this class. The toxicities observed with VEGFR TKIs are discussed separately. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p class="headingAnchor" id="H131609969"><span class="h3">Pazopanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">Pazopanib</a> is an oral agent that inhibits the TKIs associated with VEGFR, platelet-derived growth factor (PDGF) receptor, and Kit receptor.</p><p>The activity of <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> was initially demonstrated in a phase III trial that enrolled 435 patients who were randomly assigned to pazopanib or placebo, all of whom had good- or intermediate-risk disease [<a href="#rid12">12</a>]. Approximately one-half were treatment naïve and one-half had received prior cytokine therapy. Compared with placebo, pazopanib resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A significant increase in progression-free survival (PFS; median, 9 versus 4 months, hazard ratio [HR] for recurrence 0.46, 95% CI 0.34-0.62).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no improvement in OS (median, 23 versus 21 months, HR for mortality 0.91, 95% CI 0.71-1.16). However, the lack of benefit in OS was probably due to the high rate of crossover and to the use of other treatments after disease progression in patients on the placebo arm.</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Sunitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> is a TKI that inhibits VEGFR as well as other tyrosine kinases associated with the PDGF receptor and c-Kit oncogene. </p><p>Multiple schedules of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> have been evaluated in clinical studies. Based upon the results of these trials, we generally initiate sunitinib at 50 mg daily using three-week cycles of two weeks on therapy followed by one week off therapy. In the phase III trial that established its efficacy in renal cell carcinoma, sunitinib was administered at an initial dose of 50 mg daily for four weeks followed by two weeks off [<a href="#rid13">13-15</a>]. However, subsequent phase II studies [<a href="#rid16">16-20</a>] have shown that a schedule of 50 mg daily for two weeks followed by one week off is better tolerated, with reduced side effects, fewer dose reductions, and similar efficacy. Additionally, a retrospective analysis of patients switched from the four-week-on/two-week-off schedule to a two-week-on/one-week-off schedule also supported this alternative approach [<a href="#rid21">21</a>]. </p><p>The benefit of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> was initially demonstrated in a phase III trial of 750 patients with largely good- or intermediate-prognosis metastatic clear cell RCC who had not received prior systemic therapy [<a href="#rid13">13-15</a>]. In this trial, patients were randomly assigned to sunitinib or interferon alfa-2a. Compared with interferon alfa-2a, sunitinib resulted in [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A significantly higher objective response rate (47 versus 12 percent, respectively)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significantly longer PFS (median, 11 versus 5 months, HR 0.54)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer OS (median, 26.4 versus 21.8 months, HR 0.82, 95% CI 0.67-1.00)</p><p></p><p>Over one-half of all patients on both arms were treated with VEGF pathway inhibitors after completion of the trial. Multivariate analysis of survival based upon the pretreatment stratification parameters and treatment assignment found that initial treatment with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> was a statistically significant predictor of prolonged survival.</p><p><a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> is better tolerated with scheduled treatment breaks. The schedule of sunitinib used in the phase III trial above (ie, the four-week-on/two-week-off schedule) was compared with continuous daily treatment (37.5 mg/day) in a separate randomized trial that included 292 patients with advanced RCC [<a href="#rid22">22</a>]. The four-week-on/two-week-off schedule resulted in a significantly longer time to deterioration.</p><p>Although data are limited, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> appears to be efficacious regardless of age. In a retrospective study that included over 1000 previously untreated patients, there were no significant differences in PFS (median, 11 versus 10 months) and OS (26 versus 24 months) among patients &lt;70 and ≥70 years, respectively [<a href="#rid23">23</a>]. Similar results were reported among patients receiving sunitinib following progression on prior cytokine treatment. However, patients ≥70 years experienced significantly more treatment-related toxicity. Decisions on the administration of sunitinib among older patients should be based on considerations of the treatment-related risks and the goals and preferences of the individual patient.</p><p>The role of cytoreductive nephrectomy among patients treated with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> is discussed separately. (See  <a class="medical medical_review" href="/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Antiangiogenic therapy and immune checkpoint inhibitors'</a>.)</p><p class="headingAnchor" id="H131610043"><span class="h4">Pazopanib versus sunitinib</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> and <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> improve PFS (compared with placebo or interferon alfa-2a, respectively). Prospective data indicate that they result in similar survival outcomes, although pazopanib results in less toxicity, including fatigue.</p><p><a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">Pazopanib</a> and <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> have been compared in two randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In one, 1110 patients were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> or <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid24">24,25</a>]. Compared with sunitinib, pazopanib resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No difference in PFS (median, 8.4 versus 9.5 months, HR 1.05, 95% CI 0.90-1.22).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No difference in OS (median, 28.3 versus 29.1 months, HR 0.92, 95% CI 0.79-1.06).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A significantly higher objective response rate (31 versus 25 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar rate of drug discontinuation due to toxicity (24 versus 20 percent), which was predominantly driven by abnormal liver function tests (6 versus 1 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Better health-related quality of life scores, including better mouth and throat symptoms, less fatigue, and less foot soreness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PISCES trial, the tolerances of these agents were compared to evaluate if differences in toxicity affected patient preferences [<a href="#rid26">26</a>]. All patients (n = 169) were randomly assigned to a 10-week course of <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> or <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> followed by a two-week washout period. Patients then crossed over to the alternative agent for an additional 10 weeks. Following this double-blind phase, patients were allowed to continue on whichever agent they preferred. The primary endpoint was patient preference for a specific treatment as assessed by questionnaire at the end of the two treatment periods. Other endpoints were clinician preference, safety, and health-related quality of life. The main results were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the patients who completed the study questionnaires, received at least one dose of treatment during each study phase, and did not exhibit disease progression before crossover, significantly more patients preferred <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> over <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> (70 versus 22 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinicians also preferred <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> (61 percent) over <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> (22 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overall, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> resulted in a significantly better health-related quality of life, with less fatigue and less dysgeusia reported compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>.</p><p></p><p class="headingAnchor" id="H131610633"><span class="h3">Cabozantinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is a small-molecule TKI that targets VEGFR. It also inhibits the <em>MET</em> and <em>AXL</em> genes, which are associated with a poor prognosis and the development of resistance to VEGF inhibition. Cabozantinib has been compared with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> in previously treated patients and with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in previously untreated patients.</p><p>The approved dose and formulation of <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> (Cabometyx) for RCC is different from that used for metastatic medullary thyroid cancer (Cabometriq), and the two forms of cabozantinib should not be interchanged [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2119645021"><span class="h4">Cabozantinib versus everolimus</span><span class="headingEndMark"> — </span>A phase I study in previously treated patients demonstrated activity and provided the rationale for phase III evaluation [<a href="#rid28">28</a>].</p><p>In the phase III METEOR trial, 658 previously treated patients were randomly assigned to <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> (60 mg/day) or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (10 mg/day) [<a href="#rid29">29-31</a>]. All patients had progressed after receiving prior VEGF TKI therapy; 69 percent of patients had received only one prior course of systemic therapy, while 31 percent had been treated with two or more prior regimens.</p><p class="headingAnchor" id="H3790147683"><span class="h5">Efficacy</span><span class="headingEndMark"> — </span>Key efficacy results from the phase III trial included the following [<a href="#rid29">29,30,32-34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>PFS (defined by radiologic progression or by death from any cause) was the primary endpoint. PFS was significantly longer with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> compared with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (median, 7.4 versus 3.9 months, HR 0.51, 95% CI 0.41-0.62).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>OS was significantly prolonged with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> compared with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (median, 21.4 versus 17.1 months, HR 0.70, 95% CI 0.58-0.85). The improvement in OS was consistent across all preplanned subgroups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The objective response rate, based upon independent radiologic review, was significantly higher with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> (17 versus 3 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> may have particular value in patients with bone metastases, a subset that has a relatively poor prognosis in patients with advanced RCC [<a href="#rid35">35</a>]. In a secondary analysis of the 142 patients with bone metastases, cabozantinib improved both PFS survival (median 7.4 versus 2.7 months, HR 0.33, 95% CI, 0.21-0.51) and OS (median 20.1 versus 12.1 months, HR 0.54, 95% CI 0.34-0.84) compared with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H1572701334"><span class="h5">Toxicity</span><span class="headingEndMark"> — </span>All-cause toxicity in patients on the <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> arm was significant, with 68 percent of patients experiencing a grade 3 or 4 event [<a href="#rid29">29</a>]. Serious (grade ≥3) toxicities associated with cabozantinib included [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhage (2.1 versus 1.6 percent with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal perforation and/or fistula (1.2 versus 0.0 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombotic events and pulmonary emboli (7.3 versus 2.5 and 3.9 versus 0.3 percent, respectively)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (15 versus 7.1 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea (11 versus 2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Palmer-plantar erythrodysesthesia syndrome (42 versus 6 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Reversible posterior leukoencephalopathy syndrome has also been reported with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a></p><p></p><p class="headingAnchor" id="H1747143830"><span class="h4">Cabozantinib versus sunitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> was compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in previously untreated patients with intermediate- or high-risk metastatic RCC in the CABOSUN trial [<a href="#rid36">36-38</a>]. In this trial, 157 patients were randomly assigned to cabozantinib (60 mg/day) or sunitinib (50 mg/day for four weeks on each six-week cycle).</p><p class="bulletIndent1"><span class="glyph">●</span>PFS, the primary endpoint of the trial, was significantly prolonged with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> (median, 8.6 versus 5.3 months, HR 0.48, 95% CI 0.31-0.74). The objective response rate was significantly higher with cabozantinib (20 versus 9 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>OS was increased with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> (median, 26.6 versus 21.2 months), but the difference was not statistically significant (HR 0.80, 95% CI 0.53-1.21).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The safety profile was similar to that observed in the larger METEOR trial and similar to the intensity of side effects with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in this trial.</p><p></p><p class="headingAnchor" id="H110223930"><span class="h3">Axitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">Axitinib</a> is an orally available inhibitor of VEGFR1, VEGFR2, and VEGFR3. Axitinib had a higher response rate than <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in randomized clinical trials. However, axitinib has not been directly compared with <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> or <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> as initial therapy, or with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> as subsequent therapy. (See <a class="local">'Axitinib versus sorafenib'</a> below.)</p><p>Hypertension on <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> appears to be a promising biomarker of treatment response. Although titrating axitinib dosing to levels that produce hypertension may improve its efficacy both in treatment-naïve patients and in those with disease progression on immunotherapy, the benefits of this approach have not been clearly established.</p><p>In a randomized phase II trial, 213 treatment-naïve patients were treated with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> (5 mg twice daily) for four weeks and then randomly assigned to axitinib dose titration (stepwise from 5 to 7 mg to 10 mg twice a day based on tolerability) or axitinib with placebo dose titration [<a href="#rid39">39,40</a>]. Objective response rates were higher for those receiving axitinib titration versus placebo titration (54 versus 34 percent), but PFS was similar (median 14.5 versus 15.7 months, HR 0.85, 95% CI 0.54-1.35), suggesting that titrating axitinib until hypertension was observed did not influence outcomes in a majority of patients.</p><p>Among patients with disease progression on immunotherapy, the use of titrated <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> dosing as subsequent therapy remains investigational, having been evaluated only in a single phase II study [<a href="#rid41">41</a>]. Titrated dosing of axitinib has also not been directly compared in this setting with standard dosing of axitinib or other VEGF inhibitors, either as single agents (eg, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>) or in combination with other agents (eg, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>). (See <a class="local">'Overview of approach to treatment'</a> above and <a class="local">'Cabozantinib'</a> above and <a class="local">'Lenvatinib plus everolimus'</a> below.)</p><p class="headingAnchor" id="H651111644"><span class="h3">Lenvatinib plus everolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is one treatment option for patients with clear cell RCC who progress on prior antiangiogenic therapy, as this approach improved PFS over single-agent everolimus in a randomized trial [<a href="#rid42">42</a>]. When combined with everolimus, we initiate lenvatinib at 18 mg daily, which prolonged time to deterioration compared with a lower starting dose (14 mg daily) in a randomized trial [<a href="#rid43">43</a>].Patients should discontinue any prior tyrosine kinase inhibitor therapy and allow it to wash out (approximately three to five half-lives) before starting lenvatinib at 18 mg daily in combination with everolimus to avoid toxicity from overlapping antiangiogenic therapy. </p><p>In a phase II trial, 153 patients with metastatic or unresectable, locally advanced, clear cell RCC were randomly assigned to either <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (18 mg daily) plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (5 mg daily); lenvatinib (24 mg daily); or everolimus (10 mg daily) [<a href="#rid42">42</a>]. All patients had received prior antiangiogenic therapy and had an ECOG performance status 0 or 1. At median follow-up of 18 months, results were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus everolimus improved PFS (median 14.6 versus 5.5 months, HR 0.40, 95% CI 0.24-0.68). OS was also higher with the combination versus everolimus but the difference was not statistically significant (median 25.5 versus 17.5 months, HR 0.55, 95% CI 0.30-1.01). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with single-agent <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, lenvatinib plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> had a non-statistically significant trend towards higher PFS and OS (median PFS 14.6 versus 7.4 months, HR 0.66, 95% CI 0.39-1.10; median OS 25.5 versus 18.4 months, HR 0.74, 95% CI 0.40-1.36). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single-agent <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> improved PFS but not OS compared with single-agent <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (median PFS 7.4 versus 5.5 months, HR 0.61, 95% CI 0.38-0.98; median OS 18.4 versus 17.5 months, HR 0.74, 95% CI 0.42-1.31).</p><p></p><p><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is approved by the US Food and Drug Administration (FDA) as treatment for adult patients with advanced renal cell carcinoma following one prior antiangiogenic therapy. </p><p>Studies evaluating <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> as initial therapy for metastatic clear cell RCC are discussed separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a>.) </p><p class="headingAnchor" id="H3583310434"><span class="h3">Tivozanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">Tivozanib</a>, a selective VEGFR inhibitor, is active in patients who have progressed on two or more systemic therapies (including at least one prior VEGFR inhibitor). Tivozanib is one available option for patients who have progressed on both checkpoint inhibitor immunotherapy and a VEGFR inhibitor, either as single agents or in combination. In a phase III trial (TIVO-3), tivozanib improved PFS but not OS in patients with treatment-refractory RCC, including those who received prior VEGF inhibitor therapy either alone or in combination with immunotherapy [<a href="#rid11">11,44</a>]. </p><p>Data for <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a> are as follows:<strong> </strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-naïve patients </strong>– In an open-label phase III trial (TIVO-1), 517 patients with metastatic RCC who were either treatment-naïve or had progressed on prior chemotherapy or immunotherapy (but not VEGFR or mTOR inhibitors) were randomly assigned to <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a> or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid45">45</a>]. Tivozanib improved PFS in the entire study population (median 12 versus 9 months, HR 0.80, 95% CI 0.64-0.99), including those with treatment-naïve disease (median 13 versus 9 months, HR 0.76, 95% CI 0.58-0.99), but not in those with disease progression on prior chemotherapy or immunotherapy (median 12 versus 9 months, HR 0.88 95% CI 0.59-1.31). Additionally, tivozanib did not improve OS; rather, a trend towards longer survival was demonstrated in those treated with sorafenib (median 29 months each, HR 1.25, 95% CI 0.95-1.62). The lack of OS advantage with tivozanib was attributed to the crossover design of the trial; a majority of patients who progressed on sorafenib were subsequently treated with tivozanib while many of the patients initially treated with tivozanib did not receive any subsequent therapy after disease progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-refractory patients </strong>– In an open-label phase III trial (TIVO-3), 350 patients with metastatic RCC refractory to at least two previous therapies including at least one prior VEGFR inhibitor (eg, at least two VEGFR inhibitors, a VEGFR inhibitor plus immunotherapy, or VEGFR inhibitor plus other therapy) were randomly assigned to either <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a> or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid11">11</a>]. At a median follow-up of 19 months, relative to sorafenib, tivozanib improved PFS (median six versus four months, HR 0.73, 95% CI 0.56-0.94) but not OS (median 16 versus 19 months, HR 0.97, 95% CI 0.75-1.24) [<a href="#rid44">44</a>]. Tivozanib was also better tolerated with less toxicity than sorafenib [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">Tivozanib</a> is also active in patients who received prior therapy with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>. Among a subset of 172 patients in this study who received prior axitinib monotherapy either as second- or third-line therapy, subsequent therapy with tivozanib resulted in higher PFS (median six versus four months, HR 0.68) and objective response rates (13 versus 8 percent) compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid47">47</a>]. </p><p></p><p>Based on the results of the TIVO-3 study, the US FDA granted regulatory approval for <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a> in patients with advanced RCC who have progressed on two or more prior systemic therapies [<a href="#rid48">48</a>]. Based on data from the TIVO-1 trial, tivozanib also has regulatory approval in Europe as initial therapy in patients with advanced RCC disease or as subsequent therapy in those who have progressed after one prior treatment with cytokine therapy, but are treatment-naïve to VEGF or mTOR pathway inhibitors.</p><p class="headingAnchor" id="H3559180018"><span class="h2">Other agents</span></p><p class="headingAnchor" id="H131610443"><span class="h3">Sorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> is a potent small-molecule inhibitor of multiple TKIs, including VEGFR2, FLT3, PDGF receptor, and fibroblast growth factor receptor-1 (<em>FGFR1</em>)  (<a class="graphic graphic_figure graphicRef76708" href="/d/graphic/76708.html" rel="external">figure 1</a>). It also inhibits C-raf and both mutant- and wild-type B-raf. Raf kinase is an important mediator of the Ras/Raf/MEK pathway. Although activating mutations in B-raf (<em>BRAF</em>) have not been identified in RCC, constitutive activation in the BRAF pathway (Raf, MEK, and ERK) has been observed in approximately 50 percent of tumors [<a href="#rid49">49</a>].</p><p><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> is mainly limited to use as a subsequent-line molecularly targeted agent. Sorafenib does not have a clear role in the approach to previously untreated patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previously untreated patients </strong>– <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> was compared with interferon alfa-2a in a phase II trial in previously untreated patients [<a href="#rid50">50</a>]. Although greater tumor shrinkage and better quality of life were observed with sorafenib, there was no increase in PFS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previously treated patients </strong>– In the phase III TARGET trial, 903 patients with advanced RCC who had progressed despite cytokine therapy were randomly assigned to treatment with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (400 mg orally twice daily) or placebo [<a href="#rid51">51-53</a>].</p><p></p><p class="bulletIndent1">The median PFS was significantly longer in those receiving <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> compared with placebo (5.5 versus 2.8 months, HR 0.44, 95% CI 0.35-0.55). OS was not significantly prolonged with sorafenib compared with placebo (median, 17.8 versus 15.2 months, HR 0.88, 95% CI 0.74-1.04). However, the patients originally assigned to placebo could cross over to sorafenib. In a separate analysis from this trial, sorafenib appeared to be effective in carefully selected older patients (≥70 years), as evidenced by a significant improvement in PFS (26 versus 14 weeks with placebo) [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H131610748"><span class="h4">Axitinib versus sorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">Axitinib</a> is generally preferred over <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> as a VEGFR-targeted agent, based on the results of two randomized trials, which showed improvement (either a trend or significant) in PFS and response rate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-naïve patients </strong>– The role of <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> in previously untreated patients with metastatic RCC was evaluated in a multicenter randomized trial in which 288 patients were randomly assigned to treatment with axitinib (5 mg twice a day) or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (400 mg twice a day) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> resulted in a trend toward improved PFS (10 versus 6.5 months, HR 0.77, 95% CI 0.56-1.05) and a higher objective response rate (32 versus 15 percent). However, with further follow-up, there was no difference in OS between axitinib and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (median, 21.7 versus 23.3 months, HR 0.995, 95% CI 0.31-1.36) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">Axitinib</a> therapy was associated with higher rates of toxicity, including diarrhea (50 versus 40 percent), hypertension (49 versus 29 percent), weight loss (37 versus 24 percent), fatigue (33 versus 26 percent), and anorexia (29 versus 19 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previously treated patients</strong> – In the AXIS phase III trial, in which 723 patients with previously treated RCC were randomly assigned to <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> or <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid56">56,57</a>], all patients had prior treatment with a cytokine (35 percent) or other anti-VEGF or molecularly targeted treatment. Quality of life (with a time to deterioration endpoint) was prospectively assessed using standardized questionnaires.</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> resulted in a significant improvement in PFS compared with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (median, 8 versus 6 months, HR 0.66, 95% CI 0.55-0.78). The benefit was higher in patients previously treated with either cytokines (12 versus 8 months, HR 0.51, 95% CI 0.37-0.68) or <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> (6.5 versus 4.4 months, HR 0.72, 95% CI 0.57-0.90). There was a significant increase in objective response rate with axitinib (23 versus 12 percent), but there was no significant difference in OS (median, 20 versus 19 months, HR 0.96, 95% CI 0.80-1.17).</p><p></p><p class="bulletIndent1">In addition, there were no differences seen in patient-reported outcomes between the treatment groups. Among patients treated with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, the major serious (grade 3/4) adverse events were hypertension (17 percent), diarrhea (11 percent), and fatigue (10 percent). The major adverse events in those treated with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> were hand-foot syndrome (17 percent), hypertension (12 percent), and diarrhea (8 percent).</p><p></p><p class="headingAnchor" id="H131609295"><span class="h3">Bevacizumab plus interferon alfa</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> is a monoclonal antibody that binds circulating VEGF and prevents its interaction with VEGFR. Two phase III trials demonstrated improved PFS with the addition of bevacizumab to interferon alfa (either interferon alfa-2a or <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a>). However, there are no trials comparing bevacizumab plus interferon alfa with bevacizumab alone.</p><p class="bulletIndent1"><span class="glyph">●</span>In the AVOREN trial, 649 previously untreated patients were randomly assigned to interferon alfa-2a plus either <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or placebo [<a href="#rid6">6,58-60</a>]. Interferon alfa-2a plus bevacizumab improved PFS compared with interferon alfa-2a plus placebo (median, 10.2 versus 5.5 months, HR 0.63, 95% CI 0.45-0.72), and there was a trend toward improved OS (median survival, 23.3 versus 21.3 months, HR 0.86, 95% CI 0.72-1.04).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CALGB 90206 trial, 732 previously untreated patients with metastatic RCC were randomly assigned to either <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> or interferon alfa-2b plus placebo [<a href="#rid7">7,61</a>]. Treatment with bevacizumab plus interferon alfa-2b resulted in improvement in PFS (median, 8.5 versus 5.2 months, HR 0.71, 0.61-0.83) and a trend toward improved OS (median, 18.3 versus 17.4 months). Of note, interferon alfa-2b has limited availability, as the manufacturer has discontinued production.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the BEST trial (E2804), 331 patients with no prior antiangiogenic therapy were randomly assigned to <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> monotherapy, bevacizumab plus <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, bevacizumab plus <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, or sorafenib plus temsirolimus [<a href="#rid62">62</a>]. The activity of bevacizumab (as assessed by PFS) was not improved upon by the addition of either sorafenib or temsirolimus nor by the use of sorafenib plus temsirolimus. The rates of severe (grade 3 or higher) toxicity were significantly lower with bevacizumab monotherapy compared with the three combination regimens (44 versus 77 to 84 percent).</p><p></p><p class="headingAnchor" id="H63744883"><span class="h2">Toxicities of VEGF inhibition (hypertension)</span><span class="headingEndMark"> — </span>Hypertension has been consistently associated with all of the vascular endothelial growth factor (VEGF) inhibitors. Guidelines for pretreatment assessment, monitoring, and management of elevated blood pressure in patients receiving <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> are available  (<a class="graphic graphic_table graphicRef73373 graphicRef63338" href="/d/graphic/73373.html" rel="external">table 2A-B</a>). (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'</a>.)</p><p>In addition to its effects on blood pressure, preclinical studies suggest that angiotensin II can stimulate angiogenesis and tumor growth. Two retrospective analyses have found that treatment of hypertension with angiotensin system inhibitors (ASIs; including angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin receptor blockers [ARBs]) may have antitumor activity in patients with metastatic RCC [<a href="#rid63">63,64</a>]. Both studies found that ASIs significantly increased both PFS and OS, and that this effect was present in both those with pre-existing hypertension and treatment with ASIs and in those who developed hypertension during VEGF pathway inhibition and were subsequently treated with ASIs. Although there are no data from prospective trials, our approach is to use an ACEI or ARB as a component of antihypertensive treatment in patients with advanced RCC, pending additional prospective and mechanistic studies.</p><p>Other side effects associated with inhibitors of VEGF are discussed separately. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INHIBITORS OF THE mTOR PATHWAY</span><span class="headingEndMark"> — </span>The mechanistic target of rapamycin (mTOR) pathway is downstream of the phosphoinositide 3-kinase and AKT pathway that is regulated by the phosphatase and tensin homolog (<em>PTEN</em>) tumor suppressor gene  (<a class="graphic graphic_figure graphicRef65979" href="/d/graphic/65979.html" rel="external">figure 2</a>). Although mTOR inhibitors have some activity, <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>  (<a class="graphic graphic_table graphicRef68554" href="/d/graphic/68554.html" rel="external">table 3</a>) and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> have limited, if any, role in advanced RCC except for patients whose disease is refractory to initial treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) or who have mutations in the PI3K pathway.</p><p class="headingAnchor" id="H11673869"><span class="h2">Temsirolimus</span><span class="headingEndMark"> — </span>Randomized trials have shown that <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>  (<a class="graphic graphic_table graphicRef68554" href="/d/graphic/68554.html" rel="external">table 3</a>) has activity in advanced or metastatic RCC, but other options are preferred for both initial and subsequent-line therapy  (<a class="graphic graphic_algorithm graphicRef116262" href="/d/graphic/116262.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase III trial, 626 previously untreated patients were randomly assigned to <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, temsirolimus plus interferon alfa-2a, or interferon alfa-2a monotherapy [<a href="#rid65">65</a>]. Temsirolimus significantly prolonged the median overall survival (OS) compared with interferon alfa-2a as a single agent (10.9 versus 7.3 months, hazard ratio [HR] for mortality 0.73, 95% CI 0.58-0.92). There was no additional benefit from combining temsirolimus with interferon alfa-2a.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the INTORSECT trial of 512 patients who had progressed on <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> was less active than <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid66">66</a>]. OS was shorter (median, 12.3 versus 16.6 months, HR 1.31, 95% CI 1.05-1.63).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the BEST trial (E2804) of 361 patients who had not received prior targeted therapy, patients were randomly assigned to <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> as a single agent, bevacizumab plus <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, bevacizumab plus <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, or sorafenib plus temsirolimus [<a href="#rid62">62</a>]. None of the combination regimens improved progression-free survival (PFS) compared with bevacizumab monotherapy; the two combinations incorporating temsirolimus had a worse therapeutic index compared with bevacizumab monotherapy.</p><p></p><p class="headingAnchor" id="H31"><span class="h2">Everolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">Everolimus</a> is an orally administered mTOR inhibitor. Although everolimus has activity in patients with advanced RCC [<a href="#rid67">67,68</a>], randomized trials using active rather than placebo comparators have not established a role as either initial therapy or second-line therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>In the phase II RECORD-3 trial, 471 previously untreated patients were randomly assigned to either <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid69">69,70</a>]. PFS, the primary endpoint, was worse with everolimus (7.9 versus 10.7 months, HR 1.4, 95% CI 1.2-1.8). Overall PFS after crossover to sunitinib following everolimus was inferior to sunitinib followed by everolimus (21.1 versus 25.8 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In previously treated patients, several randomized trials have demonstrated that <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is less effective than <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> [<a href="#rid29">29,42,71</a>]. (See <a class="local">'Cabozantinib'</a> above and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab'</a>.)</p><p></p><p class="headingAnchor" id="H27381063"><span class="h2">Toxicity</span><span class="headingEndMark"> — </span>The mTOR inhibitors are associated with multiple side effects, although serious (grade 3 or 4) toxicities are not common.</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity reactions have been reported with <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> and may be severe or life-threatening [<a href="#rid72">72</a>]. Premedication with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> (25 to 50 mg intravenous [IV] prior to each dose of temsirolimus) is recommended. (See  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy", section on 'Temsirolimus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> were associated with pneumonitis in 0.5 to 5 percent of patients in clinical studies, which in some cases included severe toxicity and fatalities. Baseline radiographic assessment (chest radiograph or computed tomography [CT]) is advised for all patients when an mTOR inhibitor is being considered. Periodic follow-up imaging should be performed even in the absence of clinical symptoms. (See  <a class="medical medical_review" href="/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Temsirolimus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cases of opportunistic infection with <em>Pneumocystis jirovecii</em> pneumoniae, including fatalities, have been reported in patients treated with <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> [<a href="#rid73">73</a>]. Thus, close follow-up for respiratory symptoms is strongly recommended. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other frequent toxicities include asthenia, rash, anemia, nausea, anorexia, and hyperglycemia.</p><p></p><p class="headingAnchor" id="H36"><span class="h1">OTHER ISSUES</span></p><p class="headingAnchor" id="H110223769"><span class="h2">Role of VEGF inhibitors for brain metastases</span><span class="headingEndMark"> — </span>The approach to sequencing initial systemic therapies (including VEGF inhibitors) and intracranial therapies in patients with brain metastases due to RCC is discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Brain metastases, treatment naïve'</a>.)</p><p class="headingAnchor" id="H16776891"><span class="h2">Combinations of targeted agents</span><span class="headingEndMark"> — </span>The understanding of the molecular pathogenesis of RCC might make it possible to further improve the efficacy of treatment by blocking multiple steps in the same pathway ("vertical blockade") or by simultaneously inhibiting more than one pathway ("horizontal blockade"). However, even with the data from the <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> combination, there remains limited evidence that combinations are superior to sequential use of targeted agents with different mechanisms.</p><p class="headingAnchor" id="H16776907"><span class="h2">Adjuvant targeted therapy</span><span class="headingEndMark"> — </span>The role of vascular endothelial growth factor receptor (VEGFR)-targeted systemic adjuvant therapy after complete surgical resection is limited and discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy for locoregional disease'</a>.)</p><p class="headingAnchor" id="H2283610828"><span class="h2">Cytoreductive nephrectomy</span><span class="headingEndMark"> — </span>The role of cytoreductive nephrectomy among select patients treated with antiangiogenic agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Antiangiogenic therapy and immune checkpoint inhibitors'</a>.)</p><p class="headingAnchor" id="H16776912"><span class="h2">Biomarkers</span><span class="headingEndMark"> — </span>The role of various biomarkers in predicting responsiveness to molecularly targeted agents remains unknown. The use of tumor tissue and circulating biomarkers to help select therapies is not part of standard clinical practice and should be confined to prospectively designed clinical trials. </p><p class="headingAnchor" id="H2613003822"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.) </p><p class="headingAnchor" id="H37"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (See  <a class="medical medical_patient" href="/d/html/888.html" rel="external">"Patient education: Renal cell carcinoma (kidney cancer) (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – For most patients with advanced or metastatic, unresectable clear cell renal cell carcinoma (RCC), systemic therapy is typically initiated promptly with immunotherapy and/or vascular endothelial growth factor receptor (VEGFR) inhibitors. The decision to start systemic therapy and the selection of agent(s) depend on disease-related symptoms, patient comorbidities, and tumor risk stratification  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef116262" href="/d/graphic/116262.html" rel="external">algorithm 1</a>). Clinical trials are encouraged, if available. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Selection of initial therapy'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Favorable-risk disease with limited disease burden </strong>– For patients with treatment-naïve, favorable-risk disease and limited disease burden  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 1</a>), we offer close active surveillance. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Active surveillance'</a>.)</p><p></p><p class="bulletIndent2">For those who desire a more aggressive management approach, options include a single-agent VEGFR inhibitor (typically <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>) or single-agent immunotherapy (either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>). (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Limited disease burden'</a> and <a class="local">'Sunitinib'</a> above and <a class="local">'Pazopanib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Favorable-risk disease, substantial disease burden </strong>– For patients with favorable-risk disease and substantial disease burden who are symptomatic and/or have more rapidly progressive disease, we offer initial treatment with immunotherapy-based regimens. This treatment approach is discussed separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Substantial disease burden'</a>.)</p><p></p><p class="bulletIndent2">For those who are ineligible for or choose to forego initial treatment with immunotherapy-based regimens, we prefer antiangiogenic treatment that incorporates a VEGFR inhibitor. Options include <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, or <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a> and <a class="local">'Sunitinib'</a> above and <a class="local">'Pazopanib'</a> above and <a class="local">'Cabozantinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermediate- or poor-risk disease </strong>– For patients with intermediate- or poor-risk disease, we offer initial treatment with immunotherapy-based regimens. This treatment approach is discussed separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Intermediate- and poor-risk disease'</a>.)</p><p></p><p class="bulletIndent2">For those who are ineligible for or choose to forego initial treatment with immunotherapy-based regimens, we offer antiangiogenic therapy that incorporates a VEGFR inhibitor. Preferred options include <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a> and <a class="local">'Cabozantinib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment</strong> –<strong> </strong>For patients who progress after initial therapy, the choice of subsequent treatment depends on prior therapy and often includes antiangiogenic and/or molecularly targeted therapy. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Subsequent therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior immunotherapy </strong>–<strong> </strong>For patients who progress after initial immunotherapy and have not previously received antiangiogenic therapy, we suggest VEGFR-targeted therapy rather than a mechanistic target of rapamycin (mTOR) inhibitor as a single agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Options include <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, or the combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>. Treatment options incorporating further immunotherapy are discussed separately. (See <a class="local">'Preferred VEGFR inhibitors'</a> above and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Subsequent therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior immunotherapy plus a VEGFR inhibitor </strong>–<strong> </strong>For patients who progress after initial treatment with both immunotherapy and a VEGFR inhibitor (either in sequence or in combination), options include single-agent <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a>, or the combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, depending upon prior therapy. In general, when choosing treatment, we often avoid VEGFR inhibitors that have been used in prior lines of therapy. Treatment options incorporating further immunotherapy are discussed separately. (See <a class="local">'Cabozantinib'</a> above and <a class="local">'Axitinib'</a> above and <a class="local">'Tivozanib'</a> above and <a class="local">'Lenvatinib plus everolimus'</a> above and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Subsequent therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior VEGFR inhibitor alone </strong>–<strong> </strong>For patients who progress after initial treatment with a VEGFR inhibitor without previous exposure to immunotherapy, we offer single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>. Nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is an alternative option. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab'</a>.)</p><p></p><p class="bulletIndent2">For those not eligible for immunotherapy, we offer an alternative VEGFR inhibitor. (See <a class="local">'Preferred VEGFR inhibitors'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004; 64:4117.</a></li><li><a class="nounderline abstract_t">Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163.</a></li><li><a class="nounderline abstract_t">Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141.</a></li><li><a class="nounderline abstract_t">Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116:5400.</a></li><li><a class="nounderline abstract_t">Baudry E, Naoun N, Auclin E, et al. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study. Eur J Cancer 2023; 193:113292.</a></li><li><a class="nounderline abstract_t">Bracarda S, Bellmunt J, Melichar B, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int 2011; 107:214.</a></li><li><a class="nounderline abstract_t">Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137.</a></li><li><a class="nounderline abstract_t">Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4462.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Cartenì G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27:4469.</a></li><li><a class="nounderline abstract_t">Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182:29.</a></li><li><a class="nounderline abstract_t">Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 2020; 21:95.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584.</a></li><li><a class="nounderline abstract_t">Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22:295.</a></li><li><a class="nounderline abstract_t">Bjarnason GA, Khalil B, Hudson JM, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 2014; 32:480.</a></li><li><a class="nounderline abstract_t">Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014; 191:611.</a></li><li><a class="nounderline abstract_t">Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014; 50:1084.</a></li><li><a class="nounderline abstract_t">Lee JL, Kim MK, Park I, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol 2015; 26:2300.</a></li><li><a class="nounderline abstract_t">Bjarnason GA, Knox JJ, Kollmannsberger CK, et al. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. Eur J Cancer 2019; 108:69.</a></li><li><a class="nounderline abstract_t">Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2015; 26:2107.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30:1371.</a></li><li><a class="nounderline abstract_t">Hutson TE, Bukowski RM, Rini BI, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 2014; 110:1125.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370:1769.</a></li><li><a class="nounderline abstract_t">Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32:1412.</a></li><li class="breakAll">US Food and Drug Administration Label for Cabozantinib https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf (Accessed on January 02, 2021).</li><li><a class="nounderline abstract_t">Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014; 25:1603.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1814.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018; 118:1176.</a></li><li><a class="nounderline abstract_t">Donskov F, Motzer RJ, Voog E, et al. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2020; 126:1.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17:917.</a></li><li><a class="nounderline abstract_t">Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol 2018; 36:765.</a></li><li><a class="nounderline abstract_t">Powles T, Motzer RJ, Escudier B, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018; 119:663.</a></li><li><a class="nounderline abstract_t">McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014; 65:577.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol 2017; 35:591.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 2018; 94:115.</a></li><li><a class="nounderline abstract_t">George DJ, Hessel C, Halabi S, et al. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist 2019; 24:1497.</a></li><li><a class="nounderline abstract_t">Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013; 14:1233.</a></li><li><a class="nounderline abstract_t">Rini BI, Melichar B, Fishman MN, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015; 26:1372.</a></li><li><a class="nounderline abstract_t">Ornstein MC, Pal SK, Wood LS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol 2019; 20:1386.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16:1473.</a></li><li><a class="nounderline abstract_t">Bergerot C, Young Rha S, Pal S, et al. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. Oncologist 2023; 28:59.</a></li><li><a class="nounderline abstract_t">Pal SK, Escudier BJ, Atkins MB, et al. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. Eur Urol 2020; 78:783.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31:3791.</a></li><li><a class="nounderline abstract_t">Zengin ZB, Pal SK, McDermott DF, et al. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clin Genitourin Cancer 2022; 20:553.</a></li><li><a class="nounderline abstract_t">Meza L, McDermott DF, Escudier B, et al. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. Oncologist 2023; 28:e167.</a></li><li class="breakAll">US Food and Drug Administration Prescribing Label for Tivozanib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212904s000lbl.pdf (Accessed on March 22, 2021).</li><li><a class="nounderline abstract_t">Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62:2957.</a></li><li><a class="nounderline abstract_t">Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280.</a></li><li><a class="nounderline abstract_t">Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.</a></li><li><a class="nounderline abstract_t">Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312.</a></li><li><a class="nounderline abstract_t">Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; 100:1454.</a></li><li><a class="nounderline abstract_t">Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14:1287.</a></li><li><a class="nounderline abstract_t">Hutson TE, Al-Shukri S, Stus VP, et al. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clin Genitourin Cancer 2017; 15:72.</a></li><li><a class="nounderline abstract_t">Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14:552.</a></li><li><a class="nounderline abstract_t">Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103.</a></li><li><a class="nounderline abstract_t">Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19:1470.</a></li><li><a class="nounderline abstract_t">Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144.</a></li><li><a class="nounderline abstract_t">Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Manola JB, Pins M, et al. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 2015; 33:2384.</a></li><li><a class="nounderline abstract_t">Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015; 26:1128.</a></li><li><a class="nounderline abstract_t">McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21:2471.</a></li><li><a class="nounderline abstract_t">Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.</a></li><li><a class="nounderline abstract_t">Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:760.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116:4256.</a></li><li><a class="nounderline abstract_t">Knox JJ, Barrios CH, Kim TM, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 2017; 28:1339.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:2765.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.</a></li><li><a class="nounderline abstract_t">Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084.</a></li><li><a class="nounderline abstract_t">Tanaka Y, Saraya T, Kurai D, et al. Spontaneous resolution of Pneumocystis jirovecii pneumonia on high-resolution computed tomography in a patient with renal cell carcinoma. Am J Case Rep 2014; 15:496.</a></li></ol></div><div id="topicVersionRevision">Topic 2962 Version 93.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15205321" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634372" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The genetic basis of cancer of the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312463" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105118" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sunitinib rechallenge in metastatic renal cell carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37717282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20942831" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368558" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652060" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652053" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447417" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sequential sorafenib and sunitinib for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31810797" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100962" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215529" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487381" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20657034" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321258" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018239" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559686" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347107" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30648632" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216384" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430274" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24434434" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964934" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pazopanib versus sunitinib in metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785224" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687826" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687826" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827131" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A phase I study of cabozantinib (XL184) in patients with renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406150" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576624" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31887537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27279544" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309249" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30197417" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962746" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199818" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550566" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31399500" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140184" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25701454" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427205" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482279" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35881028" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32938569" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019545" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36096984" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576430" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576430" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019178" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171708" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215530" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sorafenib in advanced clear-cell renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451442" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840822" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206640" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27498023" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056247" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23598172" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156031" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408224" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368553" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936475" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077237" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795198" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724518" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538086" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297950" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18653228" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20549832" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327953" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25049330" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406148" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838439" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25396336" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Spontaneous resolution of Pneumocystis jirovecii pneumonia on high-resolution computed tomography in a patient with renal cell carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
